SentiSense
Ctrl+K
Quick tip: Press
to search stocks
A
ABBV
AbbVie Inc.
$230.11
-2.24 (-0.96%)
Summary
Stories
News
Metrics
Fundamentals
Drag to measure
Stock Reports
Upgrade to access stock reports prepared by our team with the help of AI.
What's Included
Curated Bull & Bear Case Analysis
Data-Driven Investment Perspectives
Quantified Risks & Catalysts
Expert-Curated Financial Research
Company Profile
Symbol
ABBV
Market Cap
$406.87B
IPO Date
Dec 10, 2012
CEO
Robert A. Michael
Employees
57,000
Sector
--
Industry
PHARMACEUTICAL PREPARATIONS
Country
United States
Exchange
--
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Read MoreSimilar Stocks
GILD
Gilead Sciences, Inc.
$143.93
-0.83%
REGN
Regeneron Pharmaceuticals, Inc.
$759.86
-0.66%
JNJ
Johnson & Johnson
$240.40
+0.32%
BMY
Bristol Myers Squibb Company
$60.29
-0.74%
AMGN
Amgen Inc.
$369.53
+0.53%